Overview

A Six-Step Backbone Optimization Workflow

Figure 1. Workflow of backbone optimization.

① Minimal Active Sequence Truncation → ② Alanine Scanning to Identify Key Residues → ③ Terminal Protection (N-Terminal Acetylation/C-Terminal Amidation) → ④ Protease Cleavage Site Mapping → ⑤ Backbone Modification to Improve Stability → ⑥ Formulation Development

The most commonly overlooked step is Step ④: precise mapping of protease cleavage sites. In practice, metabolic profiling is often skipped, and broad backbone modification is performed directly. This can lead to poorly targeted modification sites, loss of biological activity, and confusing structure–activity relationship (SAR) results.

Backbone Modification Strategies

Figure 2. peptide modification.

The review organizes backbone modification into several major strategies.

1. D-amino acids improve protease resistance because proteases poorly recognize unnatural chirality.
2. Aza-peptides replace C-alpha with nitrogen to lock beta-turn-like conformations.
3. N- or C-alpha alkylation can improve membrane permeability and enzyme resistance by reducing hydrogen-bond donors and increasing lipophilicity.
4. Peptoids move side chains onto nitrogen, creating protease-resistant backbones.
5. Beta- and gamma-amino acids extend the backbone and stabilize secondary structures.
6. Isosteric replacements such as depsipeptides tune hydrogen-bond networks and can reduce aggregation during synthesis.

The key principle is synergy. Stability modifications such as D-amino acids or N-methylation, conformational rigidification such as Aib or beta-amino acids, and permeability optimization can reinforce each other. However, N-methylation can disrupt intramolecular hydrogen bonds if those bonds maintain the active conformation, so SAR-guided trade-offs remain essential.

Cyclization and Bicyclic Peptides

Cyclization is another major design axis. Disulfide bonds are natural and synthetically accessible but unstable in reducing environments. Metal bridging avoids redox sensitivity but may introduce metal-related risks. Hydrocarbon stapling stabilizes alpha-helices and can improve cell penetration, but it is synthetically complex and less suitable for beta-turn targets. CLIPS-based bicyclization minimizes conformational freedom and can improve specificity, although it increases molecular weight and synthetic complexity.

Figure 3. Common chemical strategies for peptide cyclization include disulfide bridge formation, lactamization, click reactions such as CuAAC, and metal-mediated cyclization where the metal is chelated by side chains or termini.

The article presents bicyclic peptides as a structural sweet spot. Compared with monocyclic peptides, they reduce conformational entropy more strongly while still maintaining a moderate molecular weight range. They can present two binding surfaces precisely, making them attractive for broad and flat protein-protein interaction interfaces.

Half-Life Extension and Delivery

Beyond the backbone, peptide drugs can be conjugated to lipids, proteins, glycans, antibodies, nucleotides, metal chelates and nanoparticles to improve enzyme stability, plasma half-life and targeting specificity. PEGylation increases hydrodynamic radius and reduces renal clearance, but product heterogeneity is a drawback. Lipidation, as used in liraglutide and semaglutide, enables reversible albumin binding and long half-life. Fc or albumin fusion can exploit FcRn recycling, while XTEN and PAS tails create hydrophilic disordered extensions without PEG heterogeneity.

Figure 4. A peptide drug can be conjugated to various molecules to enhance properties such as enzymatic stability, plasma half-life, and target specificity.

The central tension is that stronger lipidation can improve albumin binding and half-life, but increased lipophilicity can reduce gastrointestinal permeability. This is one reason oral peptide design remains difficult.

Applications and Oral Delivery

The article reviews four major application areas. Diabetes and obesity represent the most mature trajectory, moving from insulin to GLP-1 agonists, long-acting analogs, oral semaglutide and multi-target agonists such as GLP-1/GIP and GLP-1/GIP/GCGR programs. Oncology uses peptides either as targeting heads for radiopharmaceutical delivery or as pharmacophores that interrupt signaling protein-protein interactions. Antiviral peptide programs benefit from conserved viral proteases and fusion proteins, provided in vivo stability is solved. Pain and inflammation remain challenging because many CNS targets are difficult to reach with peptides.

For oral peptide delivery, the article highlights an impossible triangle among bioavailability, molecular weight and half-life. Above approximately 1,000 Da, passive permeability drops sharply. Cyclosporin A is orally available because extensive N-methylation removes backbone hydrogen-bond donors and enables a compact membrane conformation. In the 700-1,000 Da gray zone, designers must balance N-methylation, molecular weight, lipophilicity and the chameleonic ability to switch between aqueous and membrane-compatible conformations.

Future Direction

Two strategic tensions define the next stage: oral versus injectable administration, and the precision of chemical synthesis versus the scalability of biotechnology. Hybrid approaches that combine genetic expression with post-expression chemical modification may help bridge these gaps. The largest unsolved frontier is blood-brain barrier delivery, which makes neurological disease both a major opportunity and a major barrier for peptide therapeutics.

Overview of What CD ComputaBio Can Provide

Projects inspired by this article require coordination among computational modeling, mechanism interpretation, candidate prioritization, stability assessment and translational planning. CD ComputaBio supports research-stage programs by connecting in silico analysis with practical experimental and development decisions. The following related capabilities were selected from the attached website outline because they match the technical themes discussed on this page.

Contact Us

Contact us to discuss how CD ComputaBio can support your project, from computational modeling and candidate prioritization to stability, interaction, delivery and early developability assessment. Our team can help translate a scientific concept into a practical in silico workflow and connect computational outputs with wet-lab decisions. For more information, please visit CD ComputaBio or submit an inquiry through the website contact channel.

Reference:

1. Lombardi L, Genio V D, Albericio F, et al. Advances in peptidomimetics for next-generation therapeutics: strategies, modifications, and applications. Chemical reviews, 2025, 125(15): 7099-7166. https://doi.org/10.1021/acs.chemrev.4c00989

• De Novo Design of Miniature Metallo Ketoreductases
• Nature Highlights Baker Lab's New Breakthrough: Single-Protein Artificial Virus-Like Particles Reach 220 nm in Diameter
• David Baker Lab Explores the Past, Present, and Future of Protein Design
• Nature Portfolio Journal Highlights Folddisco, a 20× Faster and 4× More Storage-Efficient Tool for Large-Scale Protein Structural Motif Search